Healthcare stocks were advancing pre-bell Friday, with the State Street Health Care Select Sector SPDR ETF (XLV) 0.5% higher and the iShares Biotechnology ETF (IBB) up 0.3%.
BeOne Medicines (ONC) stock was up more than 1% after the company said new data for tacabrutideg, a Bruton's tyrosine kinase degrader, showed "durable responses" in pretreated relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma patients and promising activity in BTK inhibitor-naive patients.
BioCryst Pharmaceuticals' (BCRX) Orladeyo was associated with "early and sustained reductions" in hereditary angioedema or HAE attacks, demonstrated by new clinical data from the ongoing APeX-P study, the company said. BioCryst Pharmaceuticals shares were up 0.1% premarket.
Rocket Pharmaceuticals (RCKT) stock was up nearly 2% after the company closed the $180 million sale of its rare pediatric disease priority review voucher.